Efficiency of interphase fluorescence <i>in situ</i>
 hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings

Akel, Salem; Kοlialexi, Aggeliki; Mavrou, Ariadni; Metaxotou, Catherine; Loukopoulos, Dimitris; Yataganas, Xenophon

doi:10.1046/j.1365-2257.2002.00470.x

Cited by 8 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27,28 Owing to the high variation of BCR-ABL-negative lymphoid cells in the samples from imatinib-treated patients, IP-FISH results show a high degree of variation and do not provide any additional information for the management of patients with CCR achieved by imatinib. Correction of IP-FISH results for nonlymphoid cells only may improve the results, 29 but is rather cumbersome and unprecise.…”

Section: Spotlightmentioning

confidence: 99%

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

et al. 2003

View full text Add to dashboard Cite

A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) a-based protocols. We sought to determine levels of residual disease in patients with MCR using various molecular methods and to establish a relation between residual BCR-ABL transcript levels and rate of relapse in complete cytogenetic remission (CCR). Response was measured by conventional cytogenetic analysis, hypermetaphase and interphase fluorescence in situ hybridization (HM-FISH, IP-FISH) of bone marrow (BM) cells, qualitative nested and quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL transcripts. We investigated 323 peripheral blood (PB) and BM samples from 48 CML patients who achieved a complete (Ph+ 0%; n ¼ 41) or partial (Ph+ 1-34%; n ¼ 7) cytogenetic remission after 3-20 months of imatinib therapy. Prior to imatinib, 35 patients were in chronic phase (CP), eight in accelerated phase (AP), four in myeloid and one in lymphoid blast crisis. HM-FISH results correlated with ratios BCR-ABL /ABL in PB and BM. In patients with CCR, residual disease was detectable by HM-FISH (31%), IP-FISH (18%), and RT-PCR (100%). During follow-up, BCR-ABL became undetectable in two patients (one CP, one AP) by both nested and quantitative RT-PCR. CCR is ongoing in 30 evaluable patients, 11 patients have relapsed. At the time of best response, median ratios BCR-ABL /ABL were 2.1% (range 0.82-7.8) in patients with subsequent relapse and 0.075% (range 0-3.9) in patients with ongoing remission (P ¼ 0.0011). All 16 CP patients, who achieved ratios BCR-ABL /ABL o0.1% as best molecular response are in continuous remission, while 6/13 patients (46%) with ratios X0.1% have relapsed (P ¼ 0.0036). We conclude that: (i) in patients with CCR to imatinib, HM-FISH and RT-PCR usually reveal residual BCR-ABL+ cells; (ii) RT-PCR results derived from PB and BM are comparable in CP CML; and (iii) low levels of residual disease with ratios BCR-ABL /ABL o0.1% are associated with continuous remission.

show abstract

Section: Spotlightmentioning

confidence: 99%

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Bone marrow and peripheral blood are comparable in many studies, but peripheral blood FISH is not always representative of the bone marrow [73][74][75], possibly because of the high and variable number of lymphocytes in the peripheral blood [76]. FISH combined with immunophenotyping can improve on these results [77]. Hypermetaphase FISH, however, is most reliably performed on bone marrow samples [9,20•].…”

Section: Discussionmentioning

confidence: 99%

Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia

Radich

2003

Curr Oncol Rep

View full text Add to dashboard Cite

The elucidation of the molecular biology of chronic myeloid leukemia (CML) has provided a paradigm for understanding leukemogenesis, targeted drug development, and disease monitoring at the molecular level. Minimal residual disease (MRD) monitoring by fluorescence in situ hybridization and polymerase chain reaction (PCR) has become an important tool in predicting relapse after allogeneic transplant, allowing for early intervention strategies such as donor lymphocyte infusion. MRD monitoring is important for assessment of disease status in patients who obtain a complete cytogenetic remission, and this approach is likely to play an important role in following patients to determine who will relapse on imatinib mesylate therapy. This review focuses primarily on MRD monitoring by PCR.

show abstract

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients

Alikian

Ellery

Forbes

et al. 2016

The Journal of Molecular Diagnostics

View full text Add to dashboard Cite

(200) 28Recent studies indicate that 40% of chronic myeloid leukaemia (CML) patients who achieve 29 sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor (TKI) therapy 30 remain disease-free after drug discontinuation. In contrast, 60% experience return of 31 detectable disease and have to re-start treatment, thus highlighting the need for an improved 32 method of identifying patients with the lowest likelihood of relapse. Here we describe the 33 validation of a personalised DNA-based digital PCR approach for quantifying very low 34 levels of residual disease, which involves the rapid identification of t(9;22) fusion junctions 35 using targeted next generation sequencing coupled with the use of a digital PCR (dPCR) 36 platform. t(9;22) genomic breakpoints were successfully mapped in samples from 32 of 32 37 patients with early disease. Disease quantification by DNA-dPCR was performed using the 38 Fluidigm BioMark platform on 46 follow-up samples from 6 of the 32 patients, including 39 36 samples that were in deep molecular remission (MR). Digital PCR detected persistent 40 disease in 81% of MR samples, out-performing both RT-dPCR (25%) and DNA-based 41 qPCR (19%). We conclude that dPCR for BCR-ABL1 DNA is the most sensitive available 42 method of residual disease detection in CML and may prove useful in the management of 43 TKI withdrawal. 44 45 3

show abstract

Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings

Cited by 8 publications

References 23 publications

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients

Contact Info

Product

Resources

About